Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial.

IF 1.9 Q3 CHEMISTRY, MEDICINAL Avicenna Journal of Phytomedicine Pub Date : 2024-07-01 DOI:10.22038/AJP.2023.23447

Akram Kooshki, Mohammad Reza Memarzadeh, Mohammad Hassan Rakhshani, Roya Akbarzadeh, Tahereh Tofighiyan, Elaheh Foroumandi

{"title":"Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial.","authors":"Akram Kooshki, Mohammad Reza Memarzadeh, Mohammad Hassan Rakhshani, Roya Akbarzadeh, Tahereh Tofighiyan, Elaheh Foroumandi","doi":"10.22038/AJP.2023.23447","DOIUrl":null,"url":null,"abstract":"Objective: This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.Materials and methods: Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.Results: Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.Conclusion: Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.","PeriodicalId":8677,"journal":{"name":"Avicenna Journal of Phytomedicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179180/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Phytomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AJP.2023.23447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients.

Materials and methods: Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.

Results: Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.

Conclusion: Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

芦荟补充剂可改善血液透析患者的心血管风险因素：一项随机、双盲、安慰剂对照试验。

目的本研究评估了补充芦荟对血液透析患者血清炎症因子、血糖和血脂的影响：将 50 名血液透析患者随机分配到芦荟组和安慰剂组。芦荟组每天服用 2 粒芦荟胶囊（500 毫克/天），连续服用 8 周。在基线和第八周结束时对血清 C 反应蛋白（hs- CRP）、空腹血糖（FBS）和血脂水平进行了评估：结果：血液透析患者补充芦荟 8 周后，血清 hs- CRP（p=0.004）、总胆固醇（p=0.01）、低密度脂蛋白（LDL）（p=0.02）水平明显降低，高密度脂蛋白（HDL）（p=0.002）浓度明显升高：结论：补充芦荟有益于改善血液透析患者的心血管风险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊